Arcturus Therapeutics Holdings Inc. (ARCT)
NASDAQ: ARCTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ARCT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $214.73M
- EPS (TTM)
- -$3.10
- Dividend yield
- None
- 52-week range
- 5.50 – 17.96
- Day range
- 7.31 – 7.73
- Volume / Avg
- 601.93K / 851.45K
- Beta
- —
- Shares outstanding
- 28.82M
52-week range
ARCT stock today
Arcturus Therapeutics (ARCT) closed at $7.45 on Nov 20, down 1.97% (-$0.15), versus the S&P 500's 3.70% decline. At this level, ARCT sits near the bottom of its 52-week range of $5.50 to $17.96: 58.5% below the high, set on Sep 17, 2026 and 35.5% above the low. ARCT is up 21.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 19.0%.
Arcturus Therapeutics has posted a net loss over the last twelve months (EPS of -$3.10), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Arcturus Therapeutics
Company profileArcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Joseph E. Payne M.Sc.
- Headquarters
- San Diego, CA
- Employees
- 106
- IPO year
- 2013
- Website
- arcturusrx.com
Financial highlights
Full financialsIn fiscal 2025, Arcturus Therapeutics generated $82.0 million in revenue, down 46.1% from fiscal 2024, its first annual decline since 2024. Arcturus Therapeutics reported a net loss of $65.8 million, compared with a loss of $80.9 million a year earlier. Operating margin was -93.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $82.03M | $152.31M | $166.80M | $206.00M | $12.36M |
| Growth | -46.14% | -8.69% | -19.03% | +1566.79% | +29.56% |
| Net income | $-65.78M | $-80.94M | $-29.73M | $9.35M | $-203.67M |
| EPS (diluted) | $-2.40 | $-3.00 | $-1.12 | $0.35 | $-7.74 |
Analyst forecast
ForecastConsensus (13 analysts)
strong_buy
Avg. price target
$23.70+218.12%
- Strong buy 1
- Buy 10
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.26 vs $-0.60
- Surprise
- +56.67%
ARCT news
All ARCT news- Arcturus Therapeutics Holdings Inc. Sells 2,466,395 Shares of Common Stock to Meiji Seika Pharma Co., Ltd. for $50.0 millionNasdaq
- Arcturus Therapeutics Announces Third Quarter 2026 Financial Results and Pipeline ProgressNasdaq
- Arcturus (ARCT) Q3 2026 Earnings Call TranscriptNasdaqARCT, UHAL.B
- Arcturus Therapeutics Announces Third Quarter 2026 Financial Results and Pipeline ProgressBusiness Wire
- Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026Business Wire
Arcturus Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PYXSPyxis Oncology Inc. | 1.81 | +7.74% | $216.49M | vs ARCT |
| KROSKeros Therapeutics Inc. | 11.08 | -2.72% | $217.44M | vs ARCT |
| RCKTRocket Pharmaceuticals Inc. | 1.95 | -7.58% | $217.74M | vs ARCT |
| IMRXImmuneering Corporation Class A | 3.38 | -2.03% | $218.90M | vs ARCT |
| CYPHCypherpunk Technologies Inc. | 1.41 | -18.02% | $210.15M | vs ARCT |
| VNDAVanda Pharmaceuticals Inc. | 3.45 | -6.13% | $208.32M | vs ARCT |
| ENTAEnanta Pharmaceuticals Inc. | 7.62 | -4.51% | $222.19M | vs ARCT |
| FTHFaeth Therapeutics Inc. | 7.88 | -9.32% | $203.65M | vs ARCT |
Indexes, lists and sector
Arcturus Therapeutics stock FAQ
What is Arcturus Therapeutics's stock price today?
ARCT last traded at $7.45 as of Nov 20, 4:00 PM EST, down 1.97% on the day. Prices are delayed at least 15 minutes.
Does Arcturus Therapeutics pay a dividend?
No. Arcturus Therapeutics does not currently pay a regular cash dividend.
Who is Arcturus Therapeutics's CEO?
Mr. Joseph E. Payne M.Sc. is the chief executive officer of Arcturus Therapeutics Holdings Inc., which has about 106 employees.
Has ARCT ever split its stock?
Yes. The most recent ARCT stock split was a 1-for-7 split on Nov 16, 2017.
What is the ARCT 52-week high?
The 52-week high for ARCT is $17.96 and the 52-week low is $5.50. The stock is currently 58.5% below its high.